Last update Aug. 16, 2022
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
喷他佐辛 is Pentazocine in Chinese.
Is written in other languages:喷他佐辛 is also known as
Main tradenames from several countries containing 喷他佐辛 in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 20 | % |
Molecular weight | 285 | daltons |
Protein Binding | 60 | % |
VD | 4.4 - 7.8 | l/Kg |
pKa | 10.4 | - |
Tmax | 1 - 3 | hours |
T½ | 2 - 3 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Pentazocine is an opioid analgesic derived from benzomorphan. It is used for the relief of moderate to severe pain, including labor pain. Oral, intramuscular, intravenous and subcutaneous administration.
A fecha de última actualización no encontramos datos publicados sobre su excreción en leche materna.
Its pharmacokinetic data (low molecular weight and moderate protein binding) makes transfer to breast milk possible, but its very high volume of distribution makes it difficult.
Its very low oral bioavailability (Sanofi 2018) minimizes the passage into plasma of the infant from ingested breast milk, except in the premature and in the immediate neonatal period in which there may be greater intestinal permeability.
It may increase prolactin levels. (Manner 1987)
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable (Sachs 2013), especially during the neonatal period and in the event of prematurity.